6533b821fe1ef96bd127c1ea

RESEARCH PRODUCT

The GERMELATOX DeCOG-trial: Attitude of German melanoma patients towards toxicity during adjuvant interferon treatment-Differences between the patient's and the physician's perspective

Christoffer GebhardtAndrea ForschnerBarbara StadeRalf GutzmerClaus GarbeElisabeth LivingstoneKatharina C. KaehlerLucie HeinzerlingTobias WagnerT. KornekPatrick TerheydenChristine BlomeAxel HauschildBerenice M. RudolphLara Valeska MaulMatthias AugustinCarmen LoquaiDirk Schadendorf

subject

OncologyCancer Researchmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentMelanomaPerspective (graphical)medicine.diseaselanguage.human_languageGermanOncologyInterferonInternal medicineToxicityImmunologymedicinelanguagebusinessneoplasmsAdjuvantmedicine.drug

description

e20099 Background: Although trials of adjuvant interferon alfa-2b (IFNa-2b) in high-risk melanoma patients suggest improvement in disease-free survival (DFS), metaanalyses showed only a marginal ov...

https://publons.com/wos-op/publon/13046983/